Tashiro H., Isacson C., Levine R., Kurman R.J., Cho K.R., and Hedrick L. p53 Gene Mutations are Common in Uterine Serous Carcinoma and Occur Early in their Pathogenesis. American Journal of Pathology, 1997; 150:177-85.

Levine R.L., Cargile C.B., Blazes M.S., van Rees B., Kurman R.J., and Ellenson L.H. PTEN Mutations and Microsatellite Instability in Complex Atypical Hyperplasia, a Precursor Lesion to Uterine Endometrioid Carcinoma. Cancer Research, 1998;58:3254-58.

Esteller M., Levine R., Bailyn S.B., Ellenson L.H., and Herman J.G. hMLH1 Promoter Hypermethylation is Associated with the Microsatellite Instability Phenotype in Sporadic Endometrial Carcinomas. Oncogene, 1998;6:2413-2417.

Schlosshauer PW, Pirog EC, Levine R.L., and Ellenson L.H. Mutational Analysis of the CTNNB1 and APC Genes in Uterine Endometrioid Carcinoma. Modern Pathology, 2000;10:1066-1071.

Levine R.L., George D.J., and Kulke M.H. Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. Clin Adv Hematol Oncol 1(2) 99-100.

Graux C., Cools J., Melotte C., Quentmeier H., Ferrando, A., Levine R., Vermeesch J.R., Stul M., Dutta B., Boeckx N., Bosly A., Heimann P., Uyttebroeck A., Somers R., MacLeod R.A.F., Drexler H.G., Look A.T., Gilliland D.G., Michaux L., Wlodarska I., Marynen P., and Hagemeijer. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nature Genetics, 2004;36:1084-1089.

Levine R.L.*, Wadleigh M.*, Sternberg D.W., Wlodarska I., Galinsky I., Stone R.M., DeAngelo D.J., Gilliland D.G., and Cools J. KIAA1509 is a novel PDGFRB fusion partner in imatinib-reponsive myeloproliferative disease associated with a t (5;14)(q33;q32). Leukemia, 2005;19:27-30. co-first authors

Levine R.L.*, Wadleigh M.*, Cools J., Ebert B.L., Wernig G., Huntly B.J.P., Boggon T.J., Wlodarska I., Clark J.J., Moore S., Adelsperger J., Koo S., Lee J.C., Gabriel S., Mercher T., D'Andrea A., Fröhling S., Dohner K., Marynen P., Vandenberghe P., Mesa R.A., Tefferi A., Griffin J.D., Eck M.J., Sellers W.R., Meyerson M., Golub T.R., Lee S.J., and Gilliland D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005;7:387-397. co-first authors

Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., Gilliland, D.G., and Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and the myelodysplastic syndrome. Blood, 2005;106:1207-1209.

Levine R.L., Loriaux M., Huntly B.J., Loh M., Beran M., Stoffregen E., Berger R., Clark J.J., Willis S.G,. Nguyen K., Flores N., Estey E., Gattermann N., Armstrong S., Look A.T., Griffin J.D., Bernard O.A., Gilliland D.G., Druker B.J., and Deininger M.W. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 2005;106:3377-3379.

Fröhling S., Lipka D.B., Kayser S., Scholl C., Schlenk R.F., Dohner H., Gilliland D.G., Levine R.L., and Dohner K. Rare occurrence of the JAK2V617F mutation in AML subtypes M5, M6, and M7. Blood, 2006;107:1242-1243.

Fröhling S., Scholl C., Gilliland D.G., and Levine R.L. Genetics of myeloid malignancies; pathogenetic and clinical implications. Journal of Clinical Oncology, 2005;23:6285-6295.

Cario H., Goerttler P.S., Steimle C., Levine R.L., and Pahl H.L. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol. 2005;130(5):800-801.

Lu X.*, Levine R.*, Tong W., Wernig G., Pikman Y., Zarnegar S., Gilliland D.G., and Lodish H. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences. 2005;102:18962-18967. co-first authors

Levine R.L., Belisle C., Wadleigh M., Lee S., Chagnon P., Gilliland D.G., and Busque L. X-Inactivation based Clonality Analysis and Quantitative JAK2V617F Assessment Reveals a Strong Association between Clonality and JAK2V617F in PV but not ET/MMM, and Identifies a Subset of JAK2V617F Negative ET and MMM Patients with Clonal Hematopoiesis. Blood, 2006;107:4139-4141

Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 2006;107(11):4274-81.

Mercher T. Wernig G., Moore S.A., Levine R.L., Gu T.L., Fröhling S., Cullen D., Polakiewicz R.D., Bernard O.A., Boggon T.J., Lee B.H., and Gilliland D.G. JAK2T875N is a novel activating mutation associated with an acute megakaryoblastic leukemia phenotype. Blood, 2006;108(8):2770-9.

Pikman Y., Lee, B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., DeAngelo D.J., Clark J.J., Lee S.J., Golub T.R., Wadleigh M., Gilliland D.G., and Levine R.L. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Public Library of Science Medicine 2006:3(7):e27.

Pardanani A., Levine R.L., Lasho T.L., Pikman Y., Mesa R.A., Wadleigh M., Steensma D.P., Elliott M.A., Wolanskyj A.P., Hogan W.J., McClure R.F., Litzow M.R., Gilliland D.G., and Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 Patients. Blood, 2006 Nov 15;108(10):3472-6.

Lasho T.L., Pardanani A., McClure R.F., Mesa R.A., Levine, R.L., Gilliland D.G., and Tefferi A. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in clonal load over time. British Journal of Haematology, 2006 Dec;135(5):683-7.

Duan Z., Bradner J., Greenberg E., Levine R., Foster R., Mahoney J., and Seiden M.V. The small molecule SD-1029, inhibits Stat3 nuclear translocation and increases chemotherapy sensitivity in human cancer cells. Clinical Cancer Research, 2006 Nov 15;12(22):6844-52.

Levine R.L. and Wernig G. Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders. Hematology American Society of Hematology Education Program, 2006;:233-9

Lee J.C., Vivanco I., Beroukhim R., Huang J.H., Feng W.L., Debiasi R.M., Yoshimoto K., King J.C., Nghiemphu P., Yuza Y., Xu Q., Greulich H., Thomas R.K., Paez J.G., Peck T.C., Linhart D.J., Glatt K.A., Getz G., Onofrio R., Ziaugra L., Levine R.L., Gabriel S., Kawaguchi T., O'neill K., Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR., Sawyers C.L., Meyerson M., Mellinghoff I.K. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. Public Library of Science Medicine, 2006 Dec 19;3(12):e485.

Levine R.L. and Gilliland D.G. JAK-2 mutations and their relevance to myeloproliferative disease. Current Opinion in Hematology, 2007 Jan;14(1):43-7.

Scott, L.M., Tong, W., Levine, R.L., Scott, M.A.., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F, Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F., and Green, A.R. Mutations of JAK2 exon 12 reveal a distinct variant of polcythemia vera. New England Journal of Medicine, 2007 Feb 1;356(5):459-68.

Mesa R.A., Verstovsek S., Cervantes F., Barosi G., Reilly J.T., Dupriez B., Levine R., Le Bousse-Kerdiles M.C., Wadleigh M., Campbell P.J., Silver R.T., Vannucchi A.M., Deeg H.J., Gisslinger H., Thomas D., Odenike O., Solberg L.A., Gotlib J., Hexner E., Nimer S.D., Kantarjian H., Orazi A., Vardiman J.W., Thiele J., Tefferi A. On behalf of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 2007 Jun;31(6):737-40.

Pardanani A., Hood J., Lasho T., Levine R.L. , Martin M.B., Noronha G., Finke C., Mak C.C., Mesa R., Zhu H., Soll R., Gilliland D.G., Tefferi A. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Aug;21(8):1658-68.

Yamamoto G., Nannya Y., Kato M., Sanada M., Levine R.L., Kawamata N., Hangaishi A., Kurokawa M., Chiba S., Gilliland D.G., Koeffler H.P., Ogawa S. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. American Journal of Human Genetics 2007 Jul;81(1):114-26. Epub 2007 Jun 5.

Levine R.L., Pardanani A., Tefferi A., Gilliland D.G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer. 2007 Sep;7(9):673-83.

Lee B.H., Tothova Z., Levine R.L., Anderson K. Byza-Vidas N., Cullen D.E., M cDowell E.P., Adelsperger J., Frohling S., Huntly B.J., Beran M., Jaconsen S.E., Gilliland D.G. FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic Leukemia. Cancer Cell 2007 Oct 12(4): 367-80.

Pikman Y. and Levine, R.L. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Curr Opin Oncol. 2007 Nov;19(6):628-634.

Fröhling S., Scholl C., Levine R.L., Loriaux M., Boggon T.J., Bernard O.A., Berger R., Döhner H., Döhner K., Ebert B.L., Teckie S., Golub T.R., Jiang J., Schittenhelm M.M., Lee B.H., Griffin J.D., Stone R.M., Heinrich M.C., Deininger M.W., Druker B.J., and Gilliland D.G. Identification of Driver and Passenger Mutations of FLT3 by High-Throughput DNA Sequence Analysis and Functional Assessment of Candidate Alleles. Cancer Cell. 2007 Dec;12(6):501-13.

Levine R.L. JAK2V617F: you can't have too much. Blood. 2008 Apr 15;111(8):3913.

Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D., Gozo M., McDowell E.P., Levine R.L., Doukas J., Mak C.C., Noronha G., Martin M., Ko Y.D., Lee B.H., Soll R., Tefferi A., Hood J.D., Gilliland D.G.G. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-2.

Loriaux M.M.*, Levine R.L. *, Tyner J.W., Fröhling S., Scholl C., Stoffregen E.P., Wernig G., Erickson H., Eide C.A., Berger R., Bernard O.A., Griffin J.D., Stone R.M., Lee B.H., Meyerson M., Heinrich M.C., Deininger M.W., Gilliland D.G., and Druker B.J. High throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008 May 1;111(9):4788-96. co-first authors

Lipka D.B., Hoffmann L.S., Heidel F., Markova B., Blum M.C., Breitenbuecher F., Kasper S., Kindler T., Levine R.L., Huber C., Fischer T. LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol Cancer Ther. 2008 May;7(5):1176-84.

Jamal R, Bélisle C, Lessard MC, Hébert J, Roy DC, Levine R, Busque L. Evidence suggesting the presence of a stem cell clone anteceding the acquisition of the JAK2-V617F mutation. Leukemia. 2008 Jul;22(7):1472-4.

Marks J.L., Gong Y., Chitale D., Golas B., McLellan M.D., Kasai Y., Ding L., Mardis E.R., Wilson R.K., Solit D., Levine R., Michel K., Thomas R.K., Rusch V.W., Ladanyi M., Pao W. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Research, 2008 Jul 15;68(14):5524-8.

Koppikar P, and Levine R.L. JAK2 and MPL mutations in myeloproliferative neoplasms. Acta Haematol. 2008;119(4):218-25.

Levine R.L. and Gilliland D.G. Myeloproliferative Disorders. Blood, 2008 Sep 15;112(6):2190-8.

Kilpivaara, O and Levine R.L. JAK2 and MPL Mutations in Myeloproliferative Neoplasms - Discovery and Science. Leukemia, 2008 Oct;22(10):1813-7.

Kawamata N., Ogawa S., Yamamoto G., Lehmann S., Levine R.L., Pikman Y., Nannya Y., Sanada M., Miller C.W., Gilliland D.G., Koeffler H.P. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Experimental Hematology, 2008 Nov;36(11):1477-85.

Brown J.R., Levine R.L., Thompson C., Basile G., Gilliland D.G., Freedman A.S. Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia, 2008 Oct;22(10):1966-9.

Levine R.L. and Heaney M. New advances in the pathogenesis and therapy of essential thrombocythemia Hematology. American Society of Hematology Education Program, 2008;76-82.

Abdel-Wahab O.I. and Levine R.L. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2008 Oct 23. [Epub ahead of print]

Bernard L., Belisle C., Mollica L., Provost S., Roy D.C., Gilliland D.G., Levine R.L., Busque L. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia 2009 Feb;23(2):287-91.

Tyner J.W., Erickson H., Deininger M.W., Willis S.G., Eide C.A., Levine R.L., Heinrich M.C., Gattermann N., Gilliland D.G., Druker B.J., Loriaux M.M. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2009 Feb 19;113(8):1749-55.

Busque L., Paquette Y., Provost S., Roy D.C., Levine R.L., Mollica L., and Gilliland D.G. Skewing of X-inactivation ratios in blood cells of aging women is confirmed by independent methodologies. Blood. 2009 Feb 6.

Tefferi A., Pardanani A., Lim K-H., Abdel-Wahab O., Lasho T.L., Patel J., Gangat N., Finke C.M., Schwager S., Mullally A., Li C-Y., Hanson C.A., Mesa R., Bernard O., Delhommeau F., Vainchenker W., Gilliland D.G., and Levine R.L. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia published online March 8, 2009.

Tefferi A., Lim K-H., Abdel-Wahab O., Lasho T.L., Patel J., Hanson C.A., Pardanani A., Gilliland D.G., and Levine R.L. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML, Leukemia published online March 8, 2009.

Kilpivaara O., Mukherjee S., Schram A.M., Wadleigh M., Mullally A., Ebert B.L., Bass A., Marubayashi S., Heguy A., Garcia-Manero G., Kantarjian H., Offit K., Stone R.M., Gilliland D.G., Klein R.J.* and Levine R.L.* A germline JAK2 SNP is associated with predisposition to the development of JAK2 V617F-positive myeloproliferative neoplasms. Nature Genetics published online March 15, 2009. co-corresponding authors

Tefferi A., Lim K-H., Abdel-Wahab O., Lasho T.L., Patel J., Hanson C.A., Pardanani A., Gilliland D.G., and Levine R.L. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML, Leukemia in press.

Mercher, T., Raffel, G.D, Moore, S.A., Cornejo, M.G., Baudry-Bluteau, D., Cagnard, N., Jesneck, J.L., Pikman, Y., Cullen, D., Williams, I.R., Akashi, K., Shigematsu, H., Bourquin, J.P., Giovannini, M., Vainchenker, W., Levine, R.L., Lee, B.H., Bernard, O.A., and Gilliland, D.G. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. Journal of Clinical Investigation published online March 17, 2009.

Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., Malinge S., Yao J.J., Kilpivaara O., Bhat R., Huberman K., Thomas S., Dolgalev I., Heguy A., Paietta E., LeBeau M., Beran M., Tallman M.S., Ebert B., Kantarjian H., Stone R.M., Gilliland D.G., Crispino J.D., and Levine R.L. Genetic Characterization of TET1, TET2, and TET3 Alterations in Myeloid Malignancies. Blood, 2009 Jul 2:114(1) 144-7.

Levine R.L. and Carroll M. A common genetic mechanism in malignant bone marrow diseases New England Journal of Medicine, 2009 May 28;360(22):2355-7.

Tefferi A., Pardanani A., Lim K-H., Abdel-Wahab O., Lasho T.L., Patel J., Gangat N., Finke C.M., Schwager S., Mullally A., Li C-Y., Hanson C.A., Mesa R., Bernard O., Delhommeau F.,  Vainchenker W., Gilliland D.G., and Levine R.L. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis, Leukemia ,2009 May;23(5):905-11.

Levine R.L. Inherited susceptibility to pediatric acute lymphoblastic leukemia. Nature Genetics, 2009 Sep;41(9):957-8.

Heinrichs S., Kulkarni R.V., Bueso-Ramos C.E., Levine R.L., Loh M.L., Li C., Neuberg, D., Kornblau S.M., Issa J-P, Gilliland D.G., Garcia-Manero G., Kantarjian H.M., Estey E.H., and Look A.T. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia, Published online April 23, 2009.

Haeno H., Levine R.L., Gilliland D.G., and Michor F. A progenitor cell origin of myeloid malignancies. Proceedings of the National Academy of Sciences, 2009 Sep:106(39):16616-16621.

Wang Y., Fiskus W., Chong D.G., Buckley K.M., Natarajan K., Rao R., Joshi A., Balusu R., Koul S., Chen J., Savoie A., Ustun C., Jillella A.P., Atadja P., Levine R.L., Bhalla K.N. Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells. Blood, 2009 Oct 14: 114: 5024-5033.

Levine R.L. Janus kinase mutations. Semin Oncol., 2009 Apr:36(2 Suppl 1):S6-11,

Levine R.L., Mechanisms of mutations in myeloproliferative neoplasms. Best Practice & Research Clinical Haematology, 2009 Oct: 22: 489-494.

Hussein K., Abdel-Wahab O., Lasho T.L., Van Dyke D.L., Levine R.L., Hanson C.A., Pardanani A., Tefferi A. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. American Journal of Hematology. 2009 Oct.

Abdel-Wahab O., Manshouri M., Patel J., Harris K., Yao J., Hedvat C., Heguy A., Bueso-Ramos C., Kantarjian H., Levine R.L.*, and Verstovsek S.* Genetic analysis of leukemic transformation of chronic myeloproliferative neoplasms. Cancer Research, 2010 70(2); 447-52. *co-corresponding authors

Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., Barretina J., Boehm J.S., Dobson J., Urashima M., McHenry K.T., Pinchback R.M., Ligon A.H., Cho Y.J., Haery L., Greulich H., Reich M., Winckler W., Lawrence M.S., Weir B.A., Tanaka K.E., Chiang D.Y., Bass A.J., Loo A., Hoffman C., Prensner J., Liefeld T., Gao Q., Yecies D., Signoretti S., Maher E., Kaye F.J., Sasaki H., Tepper J.E., Fletcher J.A., Tabernero J., Baselga J., Tsao M.S., Demichelis F., Rubin M.A., Janne P.A., Daly M.J., Nucera C., Levine R.L., Ebert B.L., Gabriel S., Rustgi A.K., Antonescu C.R., Ladanyi M., Letai A., Garraway L.A., Loda M., Beer D.G., True L.D., Okamoto A., Pomeroy S.L., Singer S., Golub T.R., Lander E.S., Getz G., Sellers W.R., Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18:(463) 899-905.

Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., Cross J.R., Fantin V.R., Hedvat C.V., Perl A.E., Rabinowitz J.D., Carroll M., Su S.M., Sharp K.A., Levine R.L., Thompson C.B. The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting a-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, 2010 March 16: 17 1-10.

Koppikar P., Abdel-Wahab O., Hedvat C., Marubayashi S., Patel J., Goel A., Kucine N., Gardner J.R., Combs A.P., Vaddi K., Haley P.J., Burn T.C., Rupar M., Bromberg J.F., Heaney M.L., De Stanchina E., Fridman J.S., Levine R.L. Efficacy of the JAK2 Inhibitor INCB16562 in a Murine Model of MPLW515L-Induced Thrombocytosis and Myelofibrosis. Blood. 2010 April 8: (115) 2919-2927.

Abdel-Wahab O., and Levine R.L. Metabolism and the leukemic stem cell. The Journal of Experimental Medicine. 2010 Apr 12;207(4):677-80.

Tefferi A., Lasho T.L., Abdel-Wahab O., Guglielmelli P., Patel J., Caramazza D., Pieri L., Finke C.M., Kilpivaara O., Wadleigh M., Mai M., McClure R.F., Gilliland D.G., Levine R.L., Pardanani A., Vannucchi A.M. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia. 2010 Apr. 23, 1-8.

Abdel-Wahab O., Kilpivaara O., Patel J., Busque L., Levine R.L. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010 July 1: Epublished.

Marubayashi S., Koppikar P., Taldone T., Abdel-Wahab O., West N., Bhagwat N., Caldas-Lopes E., Ross K.N., Gönen M., Gozman A., Ahn J.H., Rodina A., Ouerfelli O., Yang G., Hedvat C., Bradner J.E.*, Chiosis G* and Levine R.L.* HSP90 as a therapeutic target in JAK2 dependent myeloproliferative neoplasms in mice and humans. Journal of Clinical Investigation. 2010 Oct. 1; 120 (10): 3578-3593. *co-corresponding authors

Abdel-Wahab O. and Levine R.L. EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid Malignancies. Cancer Cell, 2010 Aug 17; (18) 105-107.

The Notch/Hes1 pathway sustains NF-¦ÊB activation through CYLD repression in T cell leukemia. Espinosa L., Cathelin S., D'Altri T., Trimarchi T., Statnikov A., Guiu J., Rodilla V., Ingl¨¦s-Esteve J., Nomdedeu J., Bellosillo B., Besses C., Abdel-Wahab O., Kucine N., Sun S.C., Song G., Mullighan C.C., Levine R.L., Rajewsky K., Aifantis I., Bigas A. Cancer Cell. 2010 Sep 14;18(3):268-81.

Ozawa T., Brennan C.W., Wang L., Squatrito M., Sasayama T., Nakada M., Huse J.T., Pedraza A., Utsuki S., Yasui Y., Tandon A., Fomchenko E. I., Oka H., Levine R.L., Fujii K., Ladanyi M., and Holland E.C. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes & Development, 2010 Oct 4, (24) 2205-2218.

Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Perna F., Gurvich N., Hoya-Arias R, Abdel-Wahab O., Levine R.L., Asai T., Voza F., Menendez S., Wang L., Liu F., Zhao X., Nimer SD. Blood. 2010 Oct 14;116(15):2812-21.

Bhagwat N.and Levine R.L. Metabolic Syndromes and Malignant Transformation: Where the Twain Shall Meet. Science Translational Medicine, 2010 Oct 20, Vol. 2 (54) 54ps50.

Figueroa M.E.=, Abdel Wahab O.=, Lu C.=, Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., Tallman M.S., Sun Z., Wolniak K., Peeters J.K., Wei Liu, Choe S.E., Fantin V.R., Paietta E., Löwenberg B., Licht J.D., Godley L.A., Delwel R., Valk P.J.M., Thompson C.B.*, Levine R.L.*, and Melnick A.* Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010 Dec 14;18(6):553-6. = co-first authors * co-corresponding authors

Van Vlierberghe P., Patel J., Abdel-Wahab O., Lobry C., Hedvat C.V., Balbin M., Nicolas C., Payer A.R., Fernandez H.F., Tallman M.S., Paietta E., Melnick A., Vandenberghe P., Speleman F., Aifantis I., Cools J., Levine R.L.*, and Ferrando A.A.*. PHF6 mutations in adult acute myeloid leukemia. Leukemia, 2011 Jan;25(1):130-4. *co-senior authors

ETV6-ABL1-positive CML: clinical and molecular response to tyrosine kinase inhibition with imatinib. Perna F., Abdel-Wahab O., Levine R.L., Jhanwar S.C., Imada K., Nimer S.D. Haematologica. 2010 Dec 29. [Epub ahead of print]

Liu F., Zhao X., Perna F., Wang L., Koppikar P., Abdel-Wahab O., Harr M.W., Levine R.L., Xu H., Tefferi A., Deblasio A., Hatlen M., Menendez S., Nimer S.D. JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation. Cancer Cell. 2011 Feb 15; 19 (2):283-94.


Abdel-Wahab O., Pardanani A., Patel J., Wadleigh M., Lasho T. ,Heguy A., Beran M., Gilliland D.G., Levine R.L. and Tefferi A. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011 April 11, 1-3.

Zhou L., Opalinska J., Sohal D., Yu Y., Mo Y., Bhagat T., Abdel-Wahab O., Fazzari M., Figueroa M., Alencar C., Zhang J., Kambhampati S., Parmar S., Nischal S., Hueck C., Suzuki M., Freidman E., Pellagatti A., Boultwood J., Steidl U., Sauthararajah Y., Yajnik V., Mcmahon C., Gore S.D., Platanias LC., Levine R.L., Melnick A., Wickrema A., Greally J.M., Verma A. Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q. The Journal of Biological Chemistry. 2011 April 30, 1-28.

Reddy M.M., Fernandes M.S., Salgia R., Levine R.L., Griffin J.D. and Sattler M. NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia. 12 Nov 2010, 25: 281-289.

Klinakis A., Lobry C., Abdel-Wahab O., Oh P., Haeno H., Buonamici S., DeWalle I., Cathelin S., Trimarchi T., Araldi E., Liu C., Ibrahim S., Beran M., Zavadil J., Efstratiadis A., Taghon T., Michor F., Levine R.L., and Aifantis I. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 May 12 (473): 230-235.

Abdel-Wahab O., Pardanani A., Rampal R., Lasho T., Levine R.L., and Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia. 2011 April 26 published online.

Rampal R. and Levine R.L. Finding a needle in a haystack: whole genome sequencing and mutation discovery in murine models. The Journal of Clinical Investigation. 2011 Apr 1;121(4):1255-8.

Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., Kantarjian H., Raza A., Levine R.L., Neuberg, D., and Ebert B. Clinical Effect of Point Mutations in Myelodysplastic Syndromes. The New England Journal of Medicine. 30 June 2011, 364; 26.

Moran-Crusio K.=, Reavie L.=, Shih A. =, Abdel-Wahab O.A. Ndiaye-Lobry D., Lobry C., Figueroa M., Vasanthakumar A. Patel J., Zhao X., Perna F., Pandey S., Madzo J., Song C., Dai Q., He C., Ibrahim S., Beran M., Zavadil J., Nimer S.D.,Melnick A., Godley L.,, Aifantis I.*, and Levine R.L.* Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.  Cancer Cell, 12 July 2011, 20:1-14. *co-first authors (co-corresponding authors)

Levine RL. JAK-Mutant Myeloproliferative Neoplasms.  Curr Top Microbiol Immunol. 2011 Aug 7. [Epub ahead of print]

Reddy MM, Fernandes MS, Deshpande A, Weisberg E, Inguilizian HV, Abdel-Wahab O, Kung AL, Levine RL, Griffin JD, Sattler M. The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. Leukemia. 2012 Mar;26(3):481-9. doi: 10.1038/leu.2011.225. Epub 2011 Aug 23.

Cimmino L, Abdel-Wahab O, Levine RL, Aifantis I. TET family proteins and their role in stem cell differentiation and transformation.  Cell Stem Cell. 2011 Sep 2;9(3):193-204.

Betts BC, Abdel-Wahab O, Curran SA, St Angelo ET, Koppikar P, Heller G, Levine RL, Young JW. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.  Blood. 2011 Nov 10;118(19):5330-9. Epub 2011 Sep 13.

Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011 Sep 25;7(11):818-26.

Ward PS, Cross JR, Lu C, Weigert O, Abel-Wahab O, Levine RL, Weinstock DM, Sharp KA, Thompson CB.  Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.  Oncogene. 2011 Sep 26. [Epub ahead of print]

Shih AH, Levine RL. Molecular biology of myelodysplastic syndromes.  Semin Oncol. 2011 Oct;38(5):613-20.

Abdel-Wahab O, Levine R. The spliceosome as an indicted conspirator in myeloid malignancies. Cancer Cell. 2011 Oct 18;20(4):420-3.

Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012 May;26(5):893-901. doi: 10.1038/leu.2011.294. Epub 2011 Oct 28.

Dawson MA, Bannister AJ, Saunders L, Wahab OA, Liu F, Nimer SD, Levine RL, Göttgens B, Kouzarides T, Green AR. Nuclear JAK2.  Blood. 2011 Dec 22;118(26):6987-8.

Abdel-Wahab O, Patel J, Levine RL. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am. 2011 Dec;25(6):1119-33. Epub 2011 Oct 29.

Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Sol Flaherty M, Ferres-Marco D, da Ros V, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, De Keersmaecker K, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I.  Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.  Nat Med. 2012 Jan 11. doi: 10.1038/nm.2651.

Cheng YK, Beroukhim R, Levine RL, Mellinghoff IK, Holland EC, Michor F.  A Mathematical Methodology for Determining the Temporal Order of Pathway Alterations Arising during Gliomagenesis.  PLoS Comput Biol. 2012 Jan;8(1):e1002337. Epub 2012 Jan 5.